DUBLIN–(BUSINESS WIRE)–The “Global Non-Alcoholic Steatohepatitis Market Forecast to 2028 – COVID-19 Impact and Global Analysis by Product, Application, and Sales Channel” report has been added to ResearchAndMarkets.com’s offering.
The global non-alcoholic steatohepatitis (NASH) market is projected to reach US$ 24,266.81 million by 2028 from US$ 1,631.92 million in 2021; it is expected to grow at a CAGR of 47.1% from 2021 to 2028.
Major factors driving the non-alcoholic steatohepatitis (NASH) market growth include the rising prevalence of NASH and increasing initiatives for the awareness of NASH. The growing number of clinical trials involving combination studies of drugs are likely to introduce future trends in the market during the forecast period. However, the lack of established guidelines for the diagnosis and management of NASH, and withdrawal of drugs from the marketing authorization stage of clinical trials hamper the non-alcoholic steatohepatitis (NASH) market growth.
According to the data published by the Global Liver Institute, NASH was termed as an epidemic on June 12, 2019. It affects over ~115 million people, and 357 million people are expected to be affected by this condition by 2030. Obesity, type 2 diabetes, and hyperlipidemia are substantial risk factors for NAFLD and NASH; more than ~70% of people are obese, ~75% have type 2 diabetes, and 20-80% have hyperlipidemia worldwide. NASH, if left untreated, can progress to cirrhosis and liver cancer, and raise the need for a liver transplant.
As per the data published by the American Liver Foundation, NAFLD is the most common chronic liver disease in the US. ~25% of adults in the US have been estimated to have NAFLD, of which ~20% have NASH, i.e., 5% of adults in the US. According to the NASH Education Program, NASH prevalence is expected to increase by 63% from 2015 to 2030 and NASH is predicted to become the major cause of liver transplantation in the US during 2020-2025. The American Association for the Study of Liver Diseases published a report in 2018 using Markov modeling to forecast NAFLD disease till 2030. As per the study, the prevalence of NAFLD and NASH cases is expected to increase by 21% and 63%, respectively, resulting in 33.5% and 27% prevalence rates, respectively, in adults.
Despite its increasing prevalence, NAFLD/NASH remains an under-recognized condition, and early detection is critical to reducing the risk of progression and its associated consequences. Thus, the growing prevalence of NASH drives the non-alcoholic steatohepatitis (NASH) market.
The non-alcoholic steatohepatitis (NASH) market, by product, is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others. In 2021, the others segment held the largest share of the market. The selonsertib & cenicriviroc segment is expected to register the fastest CAGR in the non-alcoholic steatohepatitis (NASH) market during the forecast period.
The non-alcoholic steatohepatitis (NASH) market, based on application, is segmented into treatment and diagnosis. In 2021, the treatment segment held a larger share of the market. However, the treatment segment is expected to register a higher CAGR during the forecast period.
The non-alcoholic steatohepatitis (NASH) market, based on distribution channel, is segmented into hospital pharmacy, retail pharmacy, and online provider. In 2021, the retail pharmacies segment held the largest share of the market. Moreover, it is expected to register the highest CAGR in the non-alcoholic steatohepatitis (NASH) market during 2021-2028.
Key Topics Covered
1. Introduction
1.1 Scope of the Study
1.2 Report Guidance
1.3 Market Segmentation
1.3.1 Global Non-Alcoholic Steatohepatitis Market – By Product
1.3.2 Global Non-Alcoholic Steatohepatitis Market – By Application
1.3.3 Global Non-Alcoholic Steatohepatitis Market – By Sales Channel
1.3.4 Global Non-Alcoholic Steatohepatitis Market – By Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Non-Alcoholic Steatohepatitis Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East And Africa PEST Analysis
4.2.5 South And Central America PEST Analysis
4.3 Experts Opinion
5. Non-alcoholic steatohepatitis (NASH) Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of NASH
5.1.2 Increasing Initiatives for the Awareness of NASH
5.2 Market Restraints
5.2.1 Lack of Established Guidelines in the Diagnosis and Management of NASH
5.2.2 Withdrawal of Drugs from Seeking Marketing Authorization for NASH
5.3 Market Opportunities
5.3.1 Growing Opportunities in Developing Nations
5.3.2 High Competition among Market Players to Manufacture the First Marketed NASH Drug Creates Global Sales Opportunity
5.4 Future Trends
5.4.1 Growing Clinical Trials Involving Combination Studies of Drugs
5.5 Impact Analysis
6. Non-alcoholic steatohepatitis (NASH) Market – Global Analysis
6.1 Global Non-Alcoholic Steatohepatitis Market Revenue Forecast and Analysis
6.2 Market Positioning Analysis of Key Players in Non-Alcoholic Steatohepatitis Market
7. Global Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts To 2028 – by Product
7.1 Overview
7.2 Product Market Revenue and Forecast Analysis (US$ Mn)
7.3 Vitamin E and Pioglitazone
7.4 Ocaliva
7.5 Elafibranor
7.6 Selonsertib & Cenicriviroc
7.7 Others
8. Global Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Application
8.1 Overview
8.2 Application Market Revenue and Forecast Analysis (US$ Mn)
8.3 Treatment
8.4 Diagnosis
9. Global Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Sales Channel
9.1 Overview
9.2 Sales Channel Market Revenue and Forecast Analysis (US$ Mn)
9.3 Hospital Pharmacy
9.4 Retail Pharmacy
9.5 Online Provider
10. Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts to 2028 – Geographical Analysis
10.1 North America: Non-Alcoholic Steatohepatitis Market
10.2 Europe: Non-alcoholic steatohepatitis (NASH) Market
10.3 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecasts To 2028
10.4 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Market
10.5 South and Central America Non-Alcoholic Steatohepatitis Market Revenue and Forecast To 2028
11. Impact of COVID-19 Pandemic on Non-alcoholic steatohepatitis (NASH) Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
11.2 Europe: Impact Assessment of COVID-19 Pandemic
11.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
11.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
11.5 South and Central America: Impact Assessment of COVID-19 Pandemic
12. Non-alcoholic steatohepatitis (NASH) Market – Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Non-Alcoholic Steatohepatitis Market
12.3 Organic Developments
12.4 Inorganic Developments
13. Company Profiles
13.1 Cadila Pharmaceuticals Ltd.
13.2 Intercept Pharmaceuticals, Inc.
13.3 Novartis AG
13.4 Galmed Pharmaceuticals.
13.5 GENFIT.
13.6 ONE WAY LIVER, S.L.
13.7 BioPredictive S.A.S
13.8 Prometheus Laboratories
13.9 Siemens Healthineers AG
13.10 Laboratory Corporation of America Holdings
For more information about this report visit https://www.researchandmarkets.com/r/vc2rii
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
